Form 4: Teva Pharmaceutical Industries Director, Sol J. Barer, Reports Acquisition of Restricted Share Units

Director Sol J. Barer reports acquisition of 17,158 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

Summary

• On June 6, 2024, Sol J. Barer, a director of Teva Pharmaceutical Industries Ltd., acquired 17,158 restricted share units.
• These restricted share units vest on June 6, 2025.
• Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.
• The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one ordinary share.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity-based compensation of Teva's directors.

Comparison to Industry Standards

• Equity compensation is a standard practice among pharmaceutical companies to align the interests of directors and shareholders.
• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize restricted stock units as part of their compensation packages for executives and directors.
• The vesting period of one year is fairly standard for restricted share units.

Stakeholder Impact

• The acquisition of restricted share units by a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates